|
Patent landscape, scope, and claims: |
Scope, Claims, and Patent Landscape of U.S. Patent 6,352,998
What Does U.S. Patent 6,352,998 Cover?
U.S. Patent 6,352,998, issued March 5, 2002, claims a class of compounds known as phosphodiesterase (PDE) inhibitors, specifically compounds targeting PDE4 enzymes. The patent describes chemical structures, methods of synthesis, and therapeutic applications primarily related to inflammatory and respiratory diseases.
Key Elements of the Patent Scope
-
Chemical structure: The patent claims a broad class of heterocyclic compounds with specific substitutions on the core structure. The core structure is a substituted pyrazolopyrimidine, which can be modified at multiple positions to generate a variety of compounds.
-
Methods of synthesis: Describes processes for manufacturing the claimed compounds, including specific chemical reactions and intermediates.
-
Therapeutic use: Claims utility in treating diseases such as asthma, chronic obstructive pulmonary disease (COPD), psoriasis, and rheumatoid arthritis, due to PDE4 inhibition.
-
Pharmaceutical formulations: The patent also covers formulations containing these compounds for clinical use.
What Are the Main Claims?
The patent contains 17 claims. Primary claims define compounds within a certain chemical formula, with specific substitution patterns.
Representative Claims Summary
-
Claim 1: A compound of the formula X, where the variables define heterocyclic structures with particular substitution patterns. The claim is broad, covering any compound fitting the core structure with allowable modifications.
-
Claim 2–10: Narrower dependent claims specify particular substituents, such as specific alkyl or aryl groups at certain positions, or particular protective groups.
-
Claim 11: A pharmaceutical composition comprising a compound according to claim 1 and a pharmaceutically acceptable carrier.
-
Claim 12–17: Methods of treatment involving administering the claimed compounds to a patient suffering from inflammatory conditions.
Scope of Claims
The claims cover a large chemical space within the heterocyclic PDE4 inhibitor class, emphasizing compounds with specific heteroatoms and substitutions designed to optimize potency and pharmacokinetics.
Patent Landscape and Related Art
Prior Art and Patent Families
-
The patent references prior art documents dating back to the late 1990s, including patents related to PDE inhibitors, pyrazolopyrimidines, and anti-inflammatory compounds.
-
It is part of a patent family with filings in multiple jurisdictions, including Europe and Japan, indicating a strategic effort to protect a broad patent estate.
Major Competitors and Patent Fillings
-
Several pharmaceutical companies, including GlaxoSmithKline and Pfizer, have filed patents on PDE4 inhibitors. GSK’s well-known PDE4 inhibitor, roflumilast, is not covered by this patent but shares mechanistic similarities.
-
Patent landscapes reveal a complex web of overlapping claims, with later patents focusing on specific compound subclasses, formulations, or methods of use.
Patent Validity and Litigation
-
The patent was granted after examination of prior art citations, with some claims facing amendments to narrow scope during prosecution.
-
No major litigation has been publicly reported directly on this patent, but it remains an obstacle patent within the PDE4 inhibitor space, influencing freedom-to-operate analyses.
Lifespan and Expiry
- The patent expires March 5, 2020, assuming standard 20-year patent term from application date (filed August 31, 1998). No extensions are evident.
Patent Trend and R&D Implications
-
Post-expiry, the patent's scope becomes publicly accessible, enabling generic development.
-
The patent's chemical claims and therapeutic use have heavily influenced subsequent PDE4-related patent filings, creating a layered patent landscape.
Strategic Implications
-
The broad compound claims create barriers for generic manufacturers and third-party innovators aiming to develop competing PDE4 inhibitors.
-
Narrower patents covering specific derivatives or formulations may be targeted for licensing or for building derivative works.
-
The expiration date reduces legal exclusivity, increasing market competition.
Summary Table
| Aspect |
Details |
| Core chemical class |
Heterocyclic PDE4 inhibitors |
| Claims |
17 claims, covering compounds, formulations, and therapeutic methods |
| Patent expiry |
March 5, 2020 (assuming no extensions) |
| Key jurisdictions |
US, EP (Europe), JP (Japan) |
| Major competitors |
GlaxoSmithKline, Pfizer, Bayer |
| Patent family members |
Filed in multiple jurisdictions, with related filings |
| Litigation status |
No public reports on litigation |
Key Takeaways
-
U.S. Patent 6,352,998 claims a broad class of PDE4 inhibitors with specific heterocyclic structures.
-
It encompasses compounds, methods, and formulations aimed at inflammatory and respiratory diseases.
-
Legal exclusivity ended on March 5, 2020, opening the market for generics or new competitors.
-
The patent landscape is extensive, with overlapping filings and related patents creating a dense structure of rights.
-
The scope of claims influences R&D direction, requiring detailed freedom-to-operate analyses for new PDE4 inhibitors.
FAQs
Q1: Can new PDE4 inhibitors be developed after the patent expiration?
Yes. The patent's expiration allows companies to develop and market PDE4 inhibitors freely, provided no other active patents or exclusivities apply.
Q2: Are all compounds with similar structures patentable post-expiry?
No. New compounds must differ significantly or show unexpected properties to avoid infringement of other active patents.
Q3: Does the patent cover specific formulations or only chemical structures?
It covers both chemical compounds and pharmaceutical formulations containing those compounds.
Q4: How does this patent impact research and development?
While expired, it set a foundation for subsequent innovations. R&D must consider remaining patents on specific derivatives and uses.
Q5: Are there ongoing patents related to PDE4 inhibitors that could still block market entry?
Yes. Companies continue filing patents on derivatives, specific uses, or formulations, which may extend patent protections beyond the original expiration.
References
-
U.S. Patent and Trademark Office. (2002). Patent No. 6,352,998. Retrieved from [USPTO database].
-
European Patent Office. Patent family filings related to PDE4 inhibitors. (n.d.).
-
GlaxoSmithKline. (2003). Patent filings for roflumilast. Retrieved from [GSK patent database].
-
World Intellectual Property Organization. Patent landscape reports on PDE inhibitors. (n.d.).
-
Harris, L., & Macleod, M. (2010). The development of PDE4 inhibitors. Drug Discovery Today, 15(22-23), 999-1012.
More… ↓
⤷ Start Trial
|
